SAB Biotherapeutics’ (SABS) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital restated their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS) in a research report released on Monday morning,Benzinga reports. The brokerage currently has a $12.00 target price on the stock.

A number of other research analysts have also recently issued reports on the company. Leerink Partnrs raised SAB Biotherapeutics to a “strong-buy” rating in a report on Wednesday, September 17th. HC Wainwright lowered their price objective on shares of SAB Biotherapeutics from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Tuesday, July 22nd. Leerink Partners assumed coverage on shares of SAB Biotherapeutics in a research report on Wednesday, September 17th. They set an “outperform” rating and a $7.00 target price on the stock. Wall Street Zen raised shares of SAB Biotherapeutics to a “sell” rating in a research note on Saturday, September 20th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of SAB Biotherapeutics in a research report on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $9.33.

SAB Biotherapeutics Stock Performance

NASDAQ:SABS opened at $3.83 on Monday. The stock has a market capitalization of $39.87 million, a P/E ratio of -1.24 and a beta of 0.60. The company has a current ratio of 10.49, a quick ratio of 0.87 and a debt-to-equity ratio of 0.02. SAB Biotherapeutics has a 1 year low of $1.00 and a 1 year high of $6.60. The firm has a 50 day moving average of $2.69 and a 200-day moving average of $2.28.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.38. As a group, sell-side analysts anticipate that SAB Biotherapeutics will post -3.69 EPS for the current fiscal year.

Institutional Investors Weigh In On SAB Biotherapeutics

Institutional investors have recently bought and sold shares of the company. Vivo Capital LLC bought a new stake in SAB Biotherapeutics during the 3rd quarter worth about $22,954,000. RA Capital Management L.P. bought a new position in shares of SAB Biotherapeutics in the 3rd quarter valued at about $8,847,000. Commodore Capital LP acquired a new stake in shares of SAB Biotherapeutics in the third quarter valued at about $8,847,000. Woodline Partners LP bought a new stake in SAB Biotherapeutics during the third quarter worth about $5,730,000. Finally, HB Wealth Management LLC acquired a new position in SAB Biotherapeutics during the third quarter valued at approximately $618,000. Institutional investors own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.